Interleukin 10 and tumor necrosis factor-α genotypes in rheumatoid arthritis - Association with clinical response to glucocorticoids

Journal of Rheumatology

Volumn 37, Issue 3, 2010, Pages 503-511

  De Paz, Banesa ^a   Alperi López, Mercedes ^b   Ballina García, Francisco J ^b   Prado, Catuxa ^a   Mozo, Lourdes ^b   Gutiérrez, Carmen ^a   Suárez, Ana ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Anticyclic Citrullinated Peptide Antibodies; Corticosteroids; Cytokines; Polymorphisms; Rheumatoid Arthritis

Indexed keywords

ADALIMUMAB; CHLOROQUINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; GLUCOCORTICOID; INTERLEUKIN 10; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POLYMORPHISM, GENETIC; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77949694141     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090566     Document Type: Article

References (51)

1. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43:30-7.
2. Deighton CM, Walker DJ, Griffiths ID, Roberts DF. The contribution of HLA to rheumatoid arthritis. Clin Genet 1989;36:178-82.
3. Kochi Y, Suzuki A, Yamada R, Yamamoto K. Genetics of rheumatoid arthritis: underlying evidence of ethnic differences. J Autoimmun 2009;32:158-62.
4. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
5. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
6. Suárez A, Castro P, Alonso R, Mozo L, Gutiérrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003;75:711-7.
7. Suárez A, López P, Mozo L, Gutiérrez C. Differential effect of IL10 and TNFa genotypes on determining susceptibility to discoid and systemic lupus erythematosus. Ann Rheum Dis 2005;64:1605-10.
8. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-9.
9. Pawlik A, Kurzawski M, Szklarz BG, Herczynska M, Drozdzik M. Interleukin-10 promoter polymorphism in patients with rheumatoid arthritis. Clin Rheumatol 2005;24:480-4.
10. Ates O, Hatemi G, Hamuryudan V, Topal-Sarikaya A. Tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients. Clin Rheumatol 2008;27:1243-8.
11. Cantagrel A, Navaux F, Loubet-Lescoulé P, Nourhashemi F, Enault G, Abbal M, et al. Interleukin-1β interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999;42:1093-100.
12. Huizinga TW, Keijsers V, Yanni G, Hall M, Ramage W, Lanchbury J, et al. Are differences in interleukin 10 production associated with joint damage? Rheumatology 2000;39:1180-8.
13. Moreno OM, González CI, Saaibi DL, Otero W, Badillo R, Martín J, et al. Polymorphisms of IL-10 gene promoter and rheumatoid arthritis in a Colombian population. Biomedica 2007;27:56-65.
14. Padyukov L, Hytönen AM, Smolnikova M, Hahn-Zoric M, Nilsson N, Hanson LA, et al. Polymorphism in promoter region of IL10 gene is associated with rheumatoid arthritis in women. J Rheumatol 2004;31:422-5.
15. Lee YH, Ji JD, Song GG. Tumor necrosis factor-a promoter -308 A/G polymorphism and rheumatoid arthritis susceptibility: a metaanalysis. J Rheumatol 2007;34:43-9.
16. Hajeer AH, Lazarus M, Turner D, Mageed RA, Vencovsky J, Sinnott P, et al. IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol 1998;27:142-5.
17. Serdaroglu M, Cakirbay H, Deger O, Cengiz S, Kul S. The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 2008;28:965-70.
18. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
19. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9.
20. van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004;50:2113-21.
21. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-34.
23. Wang J, Shete S. A test for genetic association that incorporates information about deviation from Hardy-Weinberg proportions in cases. Am J Hum Genet 2008;83:53-63.
24. Cush JJ, Splawski JB, Thomas R, McFarlin JE, Schulze-Koops H, Davis LS, et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 1995;38:96-104.
25. Mälarstig A, Eriksson P, Hamsten A, Lindahl B, Wallentin L, Siegbahn A. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart 2008;94:724-9.
26. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092-9.
27. Cantaert T, Kolln J, Timmer T, van der Pouw Kraan TC, Vandooren B, Thurlings RM, et al. B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J Immunol 2008;181:785-94.
28. Lard LR, van Gaalen FA, Schonkeren JJ, Pieterman EJ, Stoeken G, Vos K, et al. Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum 2003;48:1841-8.
29. Marinou I, Healy J, Mewar D, Moore DJ, Dickson MC, Binks MH, et al. Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis Rheum 2007;56:2549-56.
30. Castro-Santos P, Suarez A, Mozo L, Gutierrez C. Association of IL-10 and TNFa genotypes with ANCA appearance in ulcerative colitis. Clin Immunol 2007;122:108-14.
31. Schotte H, Gaubitz M, Willeke P, Tidow N, Assmann G, Domschke W, et al. Interleukin-10 promoter microsatellite polymorphisms in systemic lupus erythematosus: association with the anti-Sm immune response. Rheumatology 2004;43:1357-63.
32. Hahn-Zoric M, Hytönen AM, Hanson LA, Nilsson LA, Padyukov L. Association of -1087 IL10 and -308 TNFA gene polymorphisms with serological markers of coeliac disease. J Clin Immunol 2003;23:291-6.
33. Nemec P, Pavkova-Goldbergova M, Gatterova J, Fojtik Z, Vasku A, Soucek M. Association of the -1082 G/A promoter polymorphism of interleukin-10 gene with the autoantibodies production in patients with rheumatoid arthritis. Clin Rheumatol 2009;28:899-905.
34. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005;52:3360-70.
35. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:3371-80.
36. Chikanza IC, Kozaci DL. Corticosteroid resistance in rheumatoid arthritis: molecular and cellular perspectives. Rheumatology 2004;43:1337-45.
37. Castro-Santos P, Suarez A, López-Rivas L, Mozo L, Gutierrez C. TNFa and IL-10 gene polymorphisms in inflammatory bowel disease. Association of -1082 AA low producer IL-10 genotype with steroid dependency. Am J Gastroenterol 2006;101:1039-47.
38. Zheng HX, Webber SA, Zeevi A, Schuetz E, Zhang J, Lamba J, et al. The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. Pediatr Transplant 2004;8:551-7.
39. Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia 2002;16:1437-42.
40. Gayo A, Mozo L, Suárez A, Tuñon A, Lahoz C, Gutiérrez C. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J Neuroimmunol 1998;85:122-30.
41. Tabardel Y, Duchateau J, Schmartz D, Marécaux G, Shahla M, Barvais L, et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 1996;119:76-80.
42. Franchimont D, Martens H, Hagelstein MT, Louis E, Dewe W, Chrousos GP, et al. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999;84:2834-9.
43. Wu J, Cunha FQ, Liew FY, Weiser WY. IL-10 inhibits the synthesis of migration inhibitory factor and migration inhibitory factor-mediated macrophage activation. J Immunol 1993;151:4325-32.
44. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999;42:1601-8.
45. Calandra T, Bucala R. Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol 1997;17:77-88.
46. Kozaci DL, Chernajovsky Y, Chikanza IC. The differential expression of corticosteroid receptor isoforms in corticosteroid-resistant and -sensitive patients with rheumatoid arthritis. Rheumatology 2007;46:579-85.
47. Ho GT, Nimmo ER, Tenesa A, Fennell J, Drummond H, Mowat C, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 2005;128:288-96.
48. Bantel H, Schmitz ML, Raible A, Gregor M, Schulze-Osthoff K. Critical role of NF-kB and stress-activated protein kinases in steroid unresponsiveness. FASEB J 2002;16:1832-4.
49. Padyukov L, Lampa J, Heimbürger M, Ernestam S, Cederholm T, Lundkvist I, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526-9.
50. Seitz M, Wirthmüller U, Möller B, Villiger PM. The -308 tumour necrosis factor-a gene polymorphism predicts therapeutic response to TNF-a-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology 2007;46:93-6.
51. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. BRAGGSS. Association of RF and anti-CCP positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-TNF response in RA. Ann Rheum Dis 2009;68:69-74.